- Home
- HBT vs ARDX Comparison
HBT vs ARDX Comparison
Compare HBT & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HBT
- ARDX
- Stock Information
- Founded
- HBT 1920
- ARDX 2007
- Country
- HBT United States
- ARDX United States
- Employees
- HBT N/A
- ARDX N/A
- Industry
- HBT Major Banks
- ARDX Biotechnology: Pharmaceutical Preparations
- Sector
- HBT Finance
- ARDX Health Care
- Exchange
- HBT Nasdaq
- ARDX Nasdaq
- Market Cap
- HBT 812.0M
- ARDX 882.9M
- IPO Year
- HBT 2019
- ARDX 2014
- Fundamental
- Price
- HBT $25.80
- ARDX $6.19
- Analyst Decision
- HBT Buy
- ARDX Strong Buy
- Analyst Count
- HBT 5
- ARDX 9
- Target Price
- HBT $29.00
- ARDX $10.50
- AVG Volume (30 Days)
- HBT 22.3K
- ARDX 3.1M
- Earning Date
- HBT 10-20-2025
- ARDX 10-30-2025
- Dividend Yield
- HBT 3.32%
- ARDX N/A
- EPS Growth
- HBT 8.10
- ARDX N/A
- EPS
- HBT 2.42
- ARDX N/A
- Revenue
- HBT $229,851,000.00
- ARDX $386,146,000.00
- Revenue This Year
- HBT $8.86
- ARDX $17.79
- Revenue Next Year
- HBT $2.52
- ARDX $27.82
- P/E Ratio
- HBT $10.46
- ARDX N/A
- Revenue Growth
- HBT 4.61
- ARDX 83.88
- 52 Week Low
- HBT $19.46
- ARDX $3.21
- 52 Week High
- HBT $27.02
- ARDX $7.18
- Technical
- Relative Strength Index (RSI)
- HBT 50.84
- ARDX 53.19
- Support Level
- HBT $24.49
- ARDX $6.37
- Resistance Level
- HBT $26.43
- ARDX $6.78
- Average True Range (ATR)
- HBT 0.62
- ARDX 0.21
- MACD
- HBT -0.11
- ARDX -0.08
- Stochastic Oscillator
- HBT 51.84
- ARDX 11.94
About HBT HBT Financial Inc.
HBT Financial Inc provides a comprehensive suite of business, commercial, wealth management, and retail banking products and services to individuals, businesses, and municipal entities throughout Central and Northeastern Illinois and Eastern Iowa. It operates through one reportable segment: community banking.
About ARDX Ardelyx Inc.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.